Marijuana Emerges As Key Issue In Nevada U.S. Senate Race

Marijuana Emerges As Key Issue In Nevada U.S. Senate Race

This year’s U.S. Senate race in Nevada has become one of the most watched of the cycle, and marijuana is increasingly a central issue as Congresswoman Jacky Rosen (D) ramps up her challenge to incumbent Sen. Dean Heller (R).

During the campaign, Rosen has consistently drawn attention to what she says is Heller’s lack of pushback against U.S. Attorney General Jeff Sessions’s moves to rescind protections for state cannabis laws.

Rosen herself had written to Sessions in January, urging him to reverse his decision to end Obama-era guidance on the issue — known as the Cole Memorandum — that generally allowed states the freedom to enact legalization and regulate their own cannabis industries without federal interference.

Meanwhile, Heller also made a statement in response to Session’s decision: “Knowing Attorney General Sessions’ deference to states’ rights, I strongly encourage the DOJ to meet with Governor Sandoval and Attorney General Laxalt to discuss the implications of changes to federal marijuana enforcement policy. I also urge the DOJ to work with the congressional delegations from states like Nevada that have legalized marijuana as they review and navigate the new policy.”

However, as Rosen pointed out in January, Heller is the only Republican senator up for re-election this year who’s both from an adult use cannabis state and also voted to confirm Sessions as attorney general.

On various counts, Rosen has vocalized her support for legal marijuana — citing benefits like job creation and tax revenue — as well as her commitment to protecting state cannabis industries from federal interference, all while simultaneously attacking Heller for his relative passivity on the issue.

In addition to public commentary, Rosen has taken a stand by cosponsoring several congressional bills relating to cannabis, including the STATES Act to strengthen states’ rights on marijuana, the VA Medicinal Cannabis Research Act of 2018, the SAFE Act of 2017 to secure banking for the cannabis industry and the Regulate Marijuana Like Alcohol Act, as well as legislation to ensure tax fairness for cannabis businesses and to remove roadblocks to marijuana research.

“Nevada voters chose to legalize recreational marijuana in 2016, and states like Nevada have shown that allowing responsible adults to purchase marijuana legally supports our state budget, creates new jobs and businesses, and drives our economy instead of making our broken criminal justice system worse,” Rosen said in a press release about signing on to the Regulate Marijuana Like Alcohol Act. “I believe it’s time to end the federal prohibition on marijuana, start regulating this product like alcohol, and get rid of barriers for states like ours where voters have made this decision to move forward.”

Though publicly less vehement on the issue than Rosen is, Heller has cosponsored a handful of cannabis bills during his time in the Senate, namely the Marijuana Businesses Access to Banking Act of 2015 and the Compassionate Access, Research Expansion, and Respect States (CARERS) Act of 2015.

But he has not signed onto the CARERS Act or the banking bill in their current iterations during the 115th Congress.

Though Heller has discussed cannabis under the umbrella of states’ rights, in 2007, as a House member, he voted against an amendment shielding state medical marijuana laws from federal interference.

By 2015, Heller made a statement that “the time has come for the federal government to stop impeding the doctor-patient relationship in states that have decided their own medical marijuana policies.”

Meanwhile, NORML gave Heller a B grade in its congressional scorecard last year. Rosen will receive an A in the organization’s forthcoming analysis of the current Congress, and Heller is being downgraded to a C for “not representing his constituents,” NORML Political Director Justin Strekal told Marijuana Moment.

Since January, Rosen has been active on Twitter, posting about marijuana at least two dozen times. Heller, on the other hand, has not tweeted anything on cannabis issues.

Two years ago, Nevada voters approved legalization by a margin of 54 percent to 46 percent. This year, it could end up being the case that a contrast on cannabis issues makes the difference in what is expected to be a very close Senate race.

See the original article published on Marijuana Moment below:

Marijuana Emerges As Key Issue In Nevada U.S. Senate Race

Will New DEA Chief Signal Federal Medical Marijuana?

Will New DEA Chief Signal Federal Medical Marijuana?

While an increasing number of states consider the legalization of medical and recreational marijuana, federal authorities have continued to enforce strict Congressional laws that, technically speaking, outlaw the cultivation, possession, and use of cannabis in any form and for any reason — anywhere in the United States.

Pot-Positive POTUS?

It’s possibly not overly coincidental that Barack Obama recently spoke out in support of medical cannabis when being interviewed by Dr. Sanjay Gupta on CNN. On April 21, Attorney General Eric Holder announced that Michele Leonhart will be “retiring” her role as chief of the Drug Enforcement Administration (DEA) in May. Leonhart, depicted by even mainstream media as a Luddite who played it by the book, refused to ever admit that cannabis might offer medicinal value. Under testimony before Congress, she even refused to recognize that cannabis might be safer than hard drugs like heroin and methamphetamines.

Leonhart’s behavior has been lockstep with marijuana’s categorization under Schedule I of the Controlled Substances Act. Spanning back to the Nixon administration in 1970, this classification has prohibited the research necessary to prove the medical efficacy of cannabis for a wide range of diseases and ailments.

Recently, 20 lawmakers on the House Oversight committee logged a vote of “no confidence” for Ms. Leonhart’s leadership of the DEA. This was in response to the latest scandal involving drug cartel-funded prostitution parties in Columbia in which DEA agents participated. This inevitably led to AG Holder’s announcement.

Medical Research Needed

With no hard medical evidence, agencies like the DEA and the Department of Justice have been able to say “There’s no medical value, Schedule I makes sense.” But, in a nasty Catch 22, maintaining cannabis as a Schedule I drug has prevented the medical research necessary to prove to the government — and voters in both parties — that cannabis offers solid and significant medical benefits.

With Leonhart no longer warming the DEA chief’s seat in a few short weeks, Obama has the opportunity to prove the sincerity of his recent support for “science-based” medical cannabis — and correct his mistake of appointing Leonhart in the first place.

He can appoint a scientist or senior medical researcher, signaling the administration’s approach to all drugs to be one of health policy, not criminal enforcement. If the new chief recognized the need to reclassify cannabis as Schedule II, it would spur countless research studies and expand entrepreneurial efforts in legal states like Colorado, Washington, and Alaska.

Obama told Gupta during his interview with CNN:

“…not only do I think carefully prescribed medical use of marijuana may in fact be appropriate and we should follow the science as opposed to ideology on this issue, but I’m also on record as saying that the more we treat some of these issues related to drug abuse from a public health model and not just from an incarceration model, the better off we’re going to be.”

There is already an effort in Congress to reclassify cannabis to Schedule II that’s being spearheaded by Senators Cory Booker, Rand Paul, Kirsten Gillibrand, and Dean Heller called the CARERS (Compassionate Access, Research Expansion and Respect States) Act.

CARERS is a bipartisan bill that, if it became law, would allow states to legalize medical marijuana without federal interference. It would also allow Veterans Affairs doctors to recommend cannabis to veterans suffering from brain injury, neurological disorders, and PTSD. In addition, the bill would legalize high CBD strains of marijuana, making them viable medical treatments on a national level (especially for treatment-resistant epilepsy in both children and adults).

Is Obama Sincere?

If Obama wants to validate his own words in support of medical marijuana, he will appoint a new DEA chief that supports rescheduling and, by extension, robust research into the medical efficacy of cannabis. In addition, he should openly support the CARERS Act, possibly giving the bill the momentum it needs to become law and begin the inevitable recognition, legalization, and regulation of medical marijuana on the part of the federal government.

For a late second term president who might be looking for a positive legacy — one that doesn’t involve terrorism, war, corporate bailouts, and a lagging economy — pushing forth the first federal-level medical marijuana legislation could go a long way in terms of public opinion (all of which indicates that the majority of citizens support medical cannabis).

Subscribe To Our Newsletter

Join our mailing list to receive the latest news and updates from our team.

You have Successfully Subscribed!

[data-image-id='gourmet_bg']
[data-image-id='gourmet_bg']
[data-image-id='gourmet_bg']
[data-image-id='gourmet_bg']
[data-image-id='gourmet_bg']
[data-image-id='gourmet_bg']
[data-image-id='gourmet']
[data-image-id='gourmet']
[data-image-id='gourmet']
[data-image-id='gourmet']
[data-image-id='gourmet']
[data-image-id='gourmet']
[data-image-id='gourmet']
[data-image-id='gourmet']
[data-image-id='gourmet']
[data-image-id='gourmet']